Cargando…

Vaccination With a Single Consensus Envelope Protein Ectodomain Sequence Administered in a Heterologous Regimen Induces Tetravalent Immune Responses and Protection Against Dengue Viruses in Mice

The development of a safe and effective tetravalent dengue vaccine that elicits protection against all dengue virus (DENV) serotypes is urgently needed. The consensus sequence of the ectodomain of envelope (E) protein of DENV (cE80) has been examined as an immunogen previously. In the current study,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ran, Zheng, Xiaoyan, Sun, Jin, Feng, Kaihao, Gao, Na, Fan, Dongying, Chen, Hui, Jin, Xia, An, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524413/ https://www.ncbi.nlm.nih.gov/pubmed/31134046 http://dx.doi.org/10.3389/fmicb.2019.01113

Ejemplares similares

Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice
por: Zheng, Xiaoyan, et al.
Publicado: (2017)

Long-Term Protection Elicited by a DNA Vaccine Candidate Expressing the prM-E Antigen of Dengue Virus Serotype 3 in Mice
por: Feng, Kaihao, et al.
Publicado: (2020)

Cross-Protection Against Four Serotypes of Dengue Virus in Mice Conferred by a Zika DNA Vaccine
por: Wang, Ran, et al.
Publicado: (2019)

Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice
por: Fahimi, Hossein, et al.
Publicado: (2018)

Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate
por: Imagawa, Toshifumi, et al.
Publicado: (2021)

The Immunodominance Change and Protection of CD4(+) T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice
por: Chen, Hsin-Wei, et al.
Publicado: (2015)

Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice
por: Chiang, Chen-Yi, et al.
Publicado: (2016)

Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice
por: Kulkarni, Ajit, et al.
Publicado: (2017)

Long-term protection against dengue viruses in mice conferred by a tetravalent DNA vaccine candidate
por: Wang, Ran, et al.
Publicado: (2020)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

A tetravalent dengue nanoparticle stimulates antibody production in mice
por: Silva, Elisângela F, et al.
Publicado: (2012)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial
por: Danko, Janine R., et al.
Publicado: (2018)

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children
por: Watanaveeradej, Veerachai, et al.
Publicado: (2016)

Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera
por: Batra, Gaurav, et al.
Publicado: (2011)

Production of tetravalent dengue virus envelope protein domain III based antigens in lettuce chloroplasts and immunologic analysis for future oral vaccine development
por: van Eerde, André, et al.
Publicado: (2019)

Structure of the Core Ectodomain of the Hepatitis C Virus Envelope Glycoprotein 2
por: Khan, Abdul Ghafoor, et al.
Publicado: (2014)

Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control
por: THAVARA, U., et al.
Publicado: (2014)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines
por: Russell, Philip K., et al.
Publicado: (2016)

Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach
por: Dixit, Neeraj Kumar
Publicado: (2021)

Efficacy of Tetravalent Dengue Vaccine: A Systematic Review and Meta-Analysis
por: Khobragade, Ashish Wasudeo, et al.
Publicado: (2021)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

A stochastic B cell affinity maturation model to characterize mechanisms of protection for tetravalent dengue vaccine constructs
por: Pannala, Venkat R., et al.
Publicado: (2023)

Characterization of the Ectodomain of the Envelope Protein of Dengue Virus Type 4: Expression, Membrane Association, Secretion and Particle Formation in the Absence of Precursor Membrane Protein
por: Hsieh, Szu-Chia, et al.
Publicado: (2014)

Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia
por: Reynales, Humberto, et al.
Publicado: (2020)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
por: Rabaa, Maia A, et al.
Publicado: (2017)

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
por: DiazGranados, Carlos A, et al.
Publicado: (2020)

Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)
por: Huang, Claire Y.-H., et al.
Publicado: (2013)

In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever
por: Subramaniyan, Vijayakumar, et al.
Publicado: (2018)

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico
por: Dayan, Gustavo H, et al.
Publicado: (2014)

1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
por: Braun, Ralph, et al.
Publicado: (2021)

An Adjuvanted, Tetravalent Dengue Virus Purified Inactivated Vaccine Candidate Induces Long-Lasting and Protective Antibody Responses Against Dengue Challenge in Rhesus Macaques
por: Fernandez, Stefan, et al.
Publicado: (2015)

Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014)
por: L’Azou, Maïna, et al.
Publicado: (2018)

Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties
por: Liu, Yan, et al.
Publicado: (2014)

Plant‐expressed Fc‐fusion protein tetravalent dengue vaccine with inherent adjuvant properties
por: Kim, Mi Young, et al.
Publicado: (2018)

Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
por: El Helou, Guy, et al.
Publicado: (2020)

Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine
por: DeMaso, Christina R, et al.
Publicado: (2022)

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses
por: Nemirov, Kirill, et al.
Publicado: (2023)

Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine
por: Zhao, Hui, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_79klilaklbp53quncgiph3lt0b